Vanguard FTSE Europe ETF
VGK - ETF AI Analysis
Top Page
Vanguard FTSE Europe ETF (VGK)
VGK’s overall rating suggests it is a solid but not top-tier Europe-focused ETF, supported by several strong, diversified blue-chip holdings. High-quality companies like HSBC, Novartis, and AstraZeneca, with strong financial performance and positive earnings outlooks, are key drivers of the fund’s quality, while names such as SAP and Shell introduce some caution due to weaker technical trends and growth challenges. The main risk factor is the ETF’s concentration in European markets and sectors like pharmaceuticals and financials, which can make performance more sensitive to regional economic and regulatory conditions.
VGK vs. SPDR S&P 500 ETF (SPY)
- AUM
- 30.30B
- Region
- Europe
- Expense Ratio
- 0.06%
- Beta
- 0.74
- Issuer
- Vanguard
- Inception Date
- Mar 04, 2005
- Dividend Yield
- 2.89%
- Asset Class
- Equity
- Index Tracked
- FTSE Developed Europe All Cap
VGK Summary
VGK is the Vanguard FTSE Europe ETF, which follows the FTSE Developed Europe All Cap Index. It gives you broad exposure to many European companies across different countries and industries in a single investment. Well-known holdings include Nestlé and HSBC, along with firms in finance, healthcare, and industrials. Someone might invest in VGK to diversify beyond the U.S. market and tap into the long-term growth potential of European businesses. A key risk is that the value of the ETF can go up and down with the European stock market, so your investment may fluctuate.
How much will it cost me?
This ETF has an annual expense ratio of 0.06%, which means you’ll pay about $0.60 per year for every $1,000 invested. That’s lower than average because it’s a passively managed fund that simply tracks a European stock market index instead of paying managers to pick individual stocks.
What would affect this ETF?
VGK could benefit if Europe’s economy grows, interest rates stabilize or fall, and demand increases for its major sectors like financials, health care, and industrials, supporting companies such as ASML, HSBC, and Nestlé. On the downside, slower European growth, higher interest rates, energy price shocks, or stricter regional regulations could hurt banks, industrial firms, and consumer companies in the fund, leading to weaker overall performance.
VGK Top 10 Holdings
VGK is leaning heavily on Europe’s blue-chip health care and tech names, with ASML acting as a key engine thanks to its strong year-to-date run, even if recent momentum has cooled. Drug giants Roche and Novartis are steadily lifting the fund, while Shell’s energy rebound adds extra horsepower. On the flip side, big banks like HSBC and Banco Santander have been lagging lately, putting a brake on performance. Overall, this is a developed Europe play, spread across the UK, Switzerland, the eurozone, and broader continental markets.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.47% | $1.67B | EUR 519.88B | 58.28% | 76Outperform |
 GB:HSBA | HSBC Holdings | 2.19% | $817.24M | GBP 229.76B | 23.30% | 80Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 1.72% | $641.15M | CHF 246.17B | 27.54% | 80Outperform |
 GB:SHEL | Shell (UK) | 1.64% | $610.62M | GBP 205.39B | 25.21% | 73Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 CH:NESN | Nestlé SA | 1.51% | $562.87M | CHF 222.27B | 5.72% | 71Outperform |
 DE:SIE | Siemens | 1.45% | $542.06M | EUR 206.99B | 11.96% | 74Outperform |
 DE:SAP | SAP SE | 1.32% | $492.40M | EUR 245.13B | -2.81% | 66Neutral |
 ES:SAN | Banco Santander | 1.29% | $482.72M | EUR 163.67B | 21.32% | 73Outperform |
VGK Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VGK, the sentiment is Positive. The current price of 89.46 is above the 20-day moving average (MA) of 87.80, above the 50-day MA of 87.99, and above the 200-day MA of 87.14, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 56.42 is Neutral, neither overbought nor oversold. The STOCH value of 83.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VGK.
VGK Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VGK | $89.46 | $92.00(2.84% Upside) | $30.30B | 0.06% | 61Neutral |
 IEUR | $76.00 | $88.02(15.81% Upside) | $9.81B | 0.09% | 63Neutral |
 EZU | $67.83 | $80.19(18.21% Upside) | $9.38B | 0.50% | 63Neutral |
 BBEU | $77.96 | $90.19(15.69% Upside) | $9.24B | 0.09% | 64Neutral |
 HEDJ | $58.20 | $67.19(15.44% Upside) | $1.79B | 0.58% | 60Neutral |
 DBEU | $55.81 | $64.64(15.82% Upside) | $800.60M | 0.46% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VGK | Vanguard FTSE Europe ETF | 89.46 | 10.20 | 12.87% | |
| IEUR | iShares Core MSCI Europe ETF | 76.00 | 8.51 | 12.60% | |
| EZU | iShares MSCI Eurozone ETF | 67.83 | 6.20 | 10.05% | |
| BBEU | JPMorgan BetaBuilders Europe ETF | 77.96 | 8.58 | 12.37% | |
| HEDJ | WisdomTree Europe Hedged Equity Fund | 58.20 | 6.86 | 13.36% | |
| DBEU | Xtrackers MSCI Europe Hedged Equity ETF | 55.81 | 8.73 | 18.55% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.